We investigated the clinical significance of brain natriuretic peptide (BNP), a cardiac hormone, in chronic obstructive pulmonary disease (COPD). Subjects were 38 patients with stable COPD, of whom 20 had cor pulmonale (CP), and 22 were healthy individuals. Plasma BNP levels were measured and pulmonary arterial pressure (PAP) was estimated by echocardiography. Arterial blood gas analysis, forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV 1 ) were also recorded. BNP levels of patients with COPD were higher than those of controls (48.2 ± 37.5 and 9.3 ± 3.0 pg/ml). Patients with CP had a higher mean BNP level with respect to those without CP (73.9 ± 35.8 and 21.0 ± 10.2 pg/ml, respectively). BNP levels correlated with PAP (r = 0.68), partial arterial oxygen pressure (r = -0.70), FEV 1 (r = -0.65) and FVC (r = -0.52). We have concluded that BNP determination has a role in the diagnosis of CP in patients with COPD.
Introduction
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide, and is one of the few chronic diseases where the number of people affected is rising. Most patients present with late-stage disease, when therapeutic options are more limited. Many patients are also under-treated, over-treated or misdiagnosed. 1, 2 Cor pulmonale (CP) is a sign of poor prognosis and is the second most common cause of death in COPD. 3 Brain natriuretic peptide (BNP) is a member of the natriuretic peptides family. 4 Although originally isolated from porcine brains, BNP is a cardiac hormone which is synthesized by the heart 5, 6 and secreted into the circulation.
Elevated plasma BNP levels have been reported in patients with congestive heart failure and acute myocardial infarction. 7 Studies have also shown that plasma BNP levels may be elevated in patients with COPD 8 and that BNP blunts hypoxic pulmonary vasoconstriction in both healthy volunteers and in patients with CP, thus indicating that BNP might have a role in the pathophysiology of both pulmonary hypertension and CP. 9 In the present study, we investigated the role of BNP in COPD and its correlation with blood gas variables, pulmonary function and other clinical parameters.
Patients and methods

PATIENTS
From 1 January to 30 June 2004, 38 patients with stable COPD admitted to the Department of Pulmonary Medicine of Gulhane Military Medical Academy (GMMA) were enrolled in this study and a control group of healthy individuals was also recruited. Each subject was evaluated by means of routine biochemistry, spirometry, chest X-ray, electrocardiography (ECG) and echocardiography. Patients with systemic hypertension, pulmonary hypertension due to other causes (such as congestive heart failure, hypoalbuminaemia and renal failure) were excluded. No patient had clinical, radiological or echocardiographic evidence of left ventricular failure and none was receiving angiotensin-converting enzyme inhibitors or angiotensin-receptor antagonists. Clinical diagnosis of CP was based on: (i) Physical evidence of peripheral (ankle) oedema, increased intensity of the pulmonary component of the second heart sound or a tricuspid regurgitation murmur; (ii) Chest X-ray evidence of increased width of right descending pulmonary artery and hilar thoracic index or dilated right ventricle; (iii) ECG patterns which showed "p-pulmonale", right axis deviation or right ventricular hypertrophy. The smoking history of the patients with COPD was expressed as pack-years, defined as duration of smoking in years multiplied by mean number of packets of cigarettes smoked per day. The local ethics committee approved the study and informed consent was obtained from all participants.
MEASUREMENTS
Patients rested for at least 30 min while breathing normal air before BNP and arterial blood gas analysis (ABG), including partial pressures of arterial oxygen (PAO 2 ) and carbon dioxide (PACO 2 ) were measured. Arterial blood was taken from the radial artery for ABG. At the same time a venous blood sample, collected into a tube containing potassium EDTA, was taken for BNP analysis. PAO 2 and PACO 2 were assayed by an ABL-500 blood gas analyser. BNP was measured immediately with a commercially available Triage BNP Test (Biosite Diagnostics, La Jolla, CA, USA), which uses a fluorescence immunoassay method. The method has been described and measurement of plasma BNP levels has been validated previously in other studies. 10
PULMONARY ARTERIAL PRESSURE BY ECHOCARDIOGRAPHY
Patients were imaged in the left lateral decubitus position using a commercially available system (Vingmed 7, General Electric-Vingmed, Horten, Norway). Echocardiographic images were obtained using a 3.5-Mhz transducer in standard views. The pulsed Doppler mode was used to detect pulmonary flow with a left parasternal position at the level just proximal to the pulmonary value, without any angle correction. Tricuspid regurgitation (TR) was graded semi-quantitatively from 1 to 4, using colour Doppler echocardiography. 11 A continuous Doppler wave was used to detect tricuspid regurgitation and to calculate pulmonary arterial pressure (PAP).
Right atrial (RA) pressure was needed to calculate right ventricular systolic pressure from TR velocity, which we estimated using the diameter of the inferior vena cava measured by 2-dimensional echocardiography. 12 RA pressure was arbitrarily estimated from the diameter as follows: were assessed by standard methods.
Results
The demographic characteristics and clinical data of the study population are summarized in Table 1 . Twenty of the 38 patients with COPD were diagnosed with CP and no significant inter-group differences in age and sex were observed between patients with COPD, including those with or without CP and healthy controls. The mean BNP level in patients with COPD was significantly higher than in healthy controls (Table 1) . Separately, COPD patients complicated with CP had a higher mean BNP level (73.9 ± 35.8 pg/ml) than those without CP (21.0 ± 10.2 pg/ml; P < 0.001). The scatter diagram of the BNP levels in the study group is shown in Fig. 1 .
Patients with CP also differed significantly from those without CP with respect to mean FEV 1 , FVC, PAO 2 , PACO 2 and PAP levels ( Table  1) . Although there was a numeric difference in smoking history ( Table 1) the difference was not statistically significant.
Discriminative diagnostic values of BNP for diagnosis of CP in patients with COPD were assessed by choosing the cut-off level of 36 pg/ml, which gives 89% specificity in the group without CP. The sensitivity, specificity, PPV, NPV and DA of BNP were 75%, 89%, 89%, 76% and 82%, respectively.
The BNP levels in patients with COPD correlated significantly with PAP, PAO 2 , FEV 1 and FVC ( Table 2 ). The linear correlations of BNP with these parameters are shown in Figs 2 -5. In addition, PAP levels correlated significantly with PAO 2 , FEV 1 and FVC (Table  2 ). There was also a weak correlation with smoking history (r = 0.33) which reached significance (P = 0.044) ( Table 2 ). PACO 2 did not correlate significantly with any of the parameters.
Discussion
Our study demonstrated that plasma BNP levels are higher in patients with COPD 
Significance of BNP levels in COPD
complicated by CP than in either healthy subjects or patients without CP. We found significant correlations between BNP levels and PAO 2 , FEV 1 , FVC and PAP estimated by Doppler echocardiography. In addition, PAP levels correlated with PAO 2 , FEV 1 , FVC and weakly with smoking history. Our data suggest that plasma BNP levels are good indicators of CP in patients with COPD. Brain natriuretic peptide is produced and released from the ventricles in response to increased wall stretch and tension. Quantifying BNP levels has become a useful diagnostic tool in differentiating heart failure in patients with acute dyspnoea, although its role in the primary care setting remains to be clearly established. 14 
Nonetheless
, several studies have demonstrated that plasma BNP levels increase in patients with COPD, pulmonary embolism, BNP (pg/ml) Significance of BNP levels in COPD hypoxaemia; contrary to our findings. In addition, Bando et al. 8 found no significant differences in BNP levels between patients with chronic respiratory failure without CP and controls. Their study population consisted of 28 patients with chronic respiratory failure, of whom 13 had CP and 22 were controls; 10 lung cancer patients and 12 healthy subjects. Bando et al. 8 used a relatively small study sample, which may account for the divergence in results from those reported here.
In another previous study, 15 plasma levels of BNP were elevated with COPD compared with healthy control subjects and BNP levels correlated significantly and negatively with PAO 2 (r = -0.65; P = 0.03). Fujii et al. 17 suggested that BNP might modulate pulmonary vascular tone by interacting with endothelin-1, a potent vasoconstrictor peptide produced by the vascular endothelium. They found positive correlations between plasma levels of BNP and endothelin-1 and between BNP levels and pulmonary vascular resistance.
The clinical manifestations of CP are quite diverse and its diagnosis is difficult in daily medical practice; cardiac catheterization is required for definite diagnosis. Since this procedure is invasive, non-invasive tests such as ECG, chest radiography and echocardiography are sometimes used. The specificity and sensitivity of plasma BNP levels for detecting CP in patients with COPD were 75% and 89%, respectively, in our study. These values are more sensitive but less specific when compared with other noninvasive tests such as chest radiography (specificity 94%, sensitivity 36%), ECG (specificity 98%, sensitivity 57%) and echocardiography (specificity 94%, sensitivity 69%) as established in a multi-centre study. 21 Plasma BNP determination alone is not adequate to establish presence of CP in patients with COPD, although we consider that it helps to diagnose CP in conjunction with other non-invasive tests and clinical parameters.
Another interesting finding in the present study is the correlation of BNP with FVC and FEV 1 in patients with COPD. To the best of our knowledge this is the first time this finding has been published.
Although it has shown valuable results, our study has some limitations. Firstly PAP determination in the COPD patients was estimated by echocardiography. Cardiac catheterization is the gold standard for detecting PAP, nonetheless it has been demonstrated previously that estimation of PAP by echocardiography correlates significantly with that detected by cardiac catheterization (r = 0.693; P = 0.013). 22 Use of clinical evaluation for diagnosis of CP in patients with COPD was a further limitation of our study. We do not believe, however, that these limitations invalidate our findings.
In conclusion, our findings suggest that plasma BNP determination, as a noninvasive test, has a role in diagnosis of CP in patients with COPD. Further studies are needed to establish correlations of BNP with the long-term clinical course of COPD. This includes prognosis, hospitalization rate and survival, as well as the potential therapeutic role of BNP in COPD. 
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